ROIV 11.98 Roivant Sciences Ltd.
| Range: | 8.245-13.055 | Vol Avg: | 6121042 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | 1.25 | Cap: | 8.80B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Dec 08 2020 | Empoloyees: | 908 | ||
| CUSIP: | G76279101 | CIK: | 0001635088 | ISIN: | BMG762791017 | Country: | GB |
| CEO: | Mr. Matthew Gline | Website: | https://roivant.com | ||||
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Stock Details
ROIV 17
Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)
Corinne Jenkins·Thu Sep 19 2024
Goldman Sachs
ROIV 12.5
Roivant Sciences (ROIV) PT Raised to $12.50 at BofA Securities
Chi Fong·Wed Sep 11 2024
Bank of America Securities
ROIV 20
Piper Sandler Reiterates Overweight Rating on Roivant Sciences (ROIV)
Allison Bratzel·Fri May 31 2024
Piper Sandler
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow